Dr. Hu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Dual Hwy Ste 201
Hagerstown, MD 21740Phone+1 301-665-1712Fax+1 301-665-1714
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical Center/UCLA Stein and Doheny Eye InstitutesResidency, Ophthalmology, 2006 - 2009
- Scripps Mercy HospitalInternship, Transitional Year, 2005 - 2006
- University of California San Diego School of MedicineClass of 2005
Certifications & Licensure
- MD State Medical License 2012 - 2026
- PA State Medical License 2012 - 2026
- WV State Medical License 2013 - 2026
- CA State Medical License 2023 - 2025
- WA State Medical License 2010 - 2014
- American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- 1 citationsReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid ...Justis P Ehlers, Allen Hu, David Boyer, Scott W Cousins, Nadia K Waheed
Ophthalmology Science. 2024-10-09 - 1 citationsSafety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial.Mark R Barakat, David Brown, Allen Hu, Rahul N Khurana, Dennis Marcus
Ophthalmology Science. 2024-07-25 - 3 citationsLIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera...David Boyer, Allen Hu, David Warrow, Samantha Xavier, Victor Gonzalez
Retina. 2024-03-01
Press Mentions
- Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMDMarch 15th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: